CANADA / NICOTINE REPLACEMENT THERAPY

Nicotine pouch licensing in Canada.

Nicotine pouch licensing in Canada.

Nicotine pouch licensing in Canada.

Regulatory assessment and NPN application preparation for brands developing adult smoking-cessation products. Establish the pathway, evidence needs and label requirements before committing to a Canadian launch.

WHAT YOU RECEIVE

A defined route and a clear list of gaps.

A defined route and a clear list of gaps.

Start with a scoped assessment. Application preparation follows once the product, evidence and responsibilities are sufficiently defined. Deliverables and fees are agreed in writing.

Pathway assessment

A written assessment of the proposed Canadian product, intended use, nicotine content and regulatory route.

Formula and evidence review

Ingredient and specification questions, evidence available and gaps requiring resolution before filing.

Label and package review

Comments on mock-ups, proposed claims, brand presentation and the applicable NRT requirements.

Application plan

A document checklist, responsibilities and submission sequence. PLA preparation and response support are scoped separately.

THE CANADIAN ROUTE

Non-prescription status is not a product licence.

Non-prescription status is not a product licence.

Health Canada’s January 14, 2026 amendment clarifies that buccal pouches containing 4 mg nicotine or less per dosage unit are exempt from the Prescription Drug List and regulated as NHPs. A higher-content pouch falls under the prescription-drug framework. The NHP route requires a product licence application; the strength threshold alone does not authorise sale.

The intended use is adult smoking cessation. We assess the proposed product and its supporting evidence on that basis, including whether additional product-specific information is needed.

DESIGN AROUND THE REQUIREMENTS

Packaging and sales arrangements belong in the plan.

Packaging and sales arrangements belong in the plan.

Health Canada requires package and label mock-ups for new and pending NRT applications before a licence can be issued. Brand names, flavours, warnings and advertising need review alongside the application.

Nicotine pouches are subject to pharmacy-mediated retail access under the current rules. For dosage forms outside the self-selection list, the flavour rules allow mint, menthol or their combination. The corresponding flavour-name rules also constrain the wording on the package.

Our review identifies what must change in the proposed presentation and what remains an operational responsibility for the licence holder, manufacturer, importer or pharmacy partner.

HOW THE WORK PROCEEDS

Resolve feasibility before assembling the file.

Resolve feasibility before assembling the file.

  • Assess: review the intended product, formula, proposed use and available documents.

  • Map: identify evidence, quality, label and supply-chain gaps; agree who will resolve them.

  • Prepare: assemble the agreed application material and reconcile it with package mock-ups.

  • Support: address submission questions and change planning within the agreed engagement.

Kompete provides consulting and preparation support. Health Canada makes the licensing decision. Testing, manufacturing, specialist studies and third-party costs are agreed separately; timelines depend on the evidence gaps and regulatory review.

Questions to settle early.

Questions to settle early.

Can an overseas pouch be sold unchanged in Canada?

An overseas listing or approval does not establish Canadian compliance. Start with the actual formula, intended use, evidence and package.

Does 4 mg automatically qualify for an NPN?

No. The prescription-status exemption and the assessment of an NHP application are separate questions. A complete, supportable application is still needed.

Do you guarantee approval or a filing date?

Scope and a work plan follow the initial document review. Approval rests with Health Canada, and unresolved evidence or manufacturing issues can affect timing.

START WITH YOUR PRODUCT

Bring the formula, intended use and current evidence.

Bring the formula, intended use and current evidence.

Share a brief covering nicotine content per pouch, intended smoking-cessation use, proposed formula, manufacturer, existing studies and package status. We will identify a useful first scope and arrange document sharing.

Regulatory sources checked 16 November 2026. Product-specific requirements are reviewed when the engagement is scoped.